An Unusual Case of Esophageal Thickening

Document Type

Conference Proceeding

Publication Date

10-2023

Publication Title

American Journal of Gastroenterology

Abstract

Introduction: Eosinophilic esophagitis (EoE) is characterized by clinical features of esophageal dysfunction and pathological features of eosinophilic inflammation. We present a case of a gentleman with dysphagia who was diagnosed to have EoE based on submucosal eosinophilic infiltrate and evidence of esophageal thickening on imaging. Case Description/Methods: A 52-year-old man with long-standing GERD and allergic rhinitis presented with new-onset dysphagia and epigastric pain for the past several weeks. His home medications included omeprazole and cetirizine. Lab work revealed peripheral eosinophilia (2.1x109/L). The esophageal mucosa appeared unremarkable on EGD except for concern for mild extrinsic esophageal stenosis. Subsequent CT scan showed circumferential thickening throughout the length of esophagus concerning for neoplasm. He then underwent an endoscopic ultrasound (EUS) which showed diffuse circumferential thickening with esophageal total wall thickness (TWT) 10 mm, primarily due to thickening of layers 2 and 3 (deep mucosa and submucosa) (Figure 1A). Deep bite-on-bite biopsies revealed marked eosinophilic infiltrate in the submucosa (30 eosinophils per high power field [HPF]) but not in the mucosal layer (2/ HPF). The patient was started on prednisone taper which was later switched to swallowed fluticasone. Excellent symptomatic relief was obtained with follow-up EUS 4 months later showing improvement in TWT (6 mm; Figure 1B) and resolution of peripheral eosinophilia (0.2 x 109/L). He is now on dupilumab with complete resolution of his symptoms. Discussion: EoE is typically diagnosed on the basis of histopathology showing $15 eosinophils/HPF. Endoscopic findings consist of loss of normal mucosal vascular pattern, stacked concentric rings, strictures and linear furrows, although patients may have a normal endoscopic appearance. There have been rare reports of primary submucosal involvement,1 as seen in our patient. Treatment options include elimination diets, PPI, topical glucocorticoids, and dupilumab, which was recently approved by the FDA

Volume

118

Issue

10S

First Page

S1927

Comments

American College of Gastroenterology Annual Scientific Meeting, October 20-25, 2023, Vancouver, Canada

DOI

10.14309/01.ajg.0000960980.71660.12

Link to Full Text

Share

COinS